Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Overview

Founded 1995
Founded
Status Public
Employees 184
Employees
Stock Symbol LXRX
Stock Symbol
Investments 3
Share Price $1.89 (As of Thursday Closing)

Lexicon Pharmaceuticals General Information

Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Contact Information

Formerly Known As
Lexicon Genetics
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 8800 Technology Forest Place
  • The Woodlands, TX 77381
  • United States
+1 (281) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexicon Pharmaceuticals Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.89 $1.89 $1.12 - $6.72 $202M 107M 944K $0.80

Lexicon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 183,217 389,850 760,993 946,535
Revenue 320,856 322,073 63,209 91,689
EBITDA 100,135 145,099 (99,596) (127,225)
Net Income 85,319 130,133 (120,548) (122,993)
Total Assets 370,567 417,715 284,136 436,539
Total Debt 245,222 246,285 245,002 245,670
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexicon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Intercept(Biotechnology) Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
00000 000000000000 Venture Capital-Backed San Diego, CA 00 0000 000000 - 000 0000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Charlottesville, VA 00 000.00 00000000000 000.00

Lexicon Pharmaceuticals Executive Team (12)

Name Title Board Seat Contact Info
Lonnel Coats Chief Executive Officer & Board Member
Jeffrey Wade JD Chief Financial Officer, Finance & Executive Vice President
James Tessmer Chief Accounting Officer, Accounting & Vice President
Alexander Santini Executive Vice President & Executive
Pablo Lapuerta MD Chief Medical Officer & Executive Vice President

5 Former Executives

Lexicon Pharmaceuticals Board Members (9)

To view Lexicon Pharmaceuticals‘s full board member team, request access »
Name Representing Role Since
0000 0000 00 Self Board Member 000 0000
00000000000 0000000 The Invus Group Board Member 000 0000
00000 000000000 Self Board Member 000 0000
000000 00000 Self Board Member 000 0000
000000 00000 Lexicon Pharmaceuticals Chief Executive Officer & Board Member 000 0000

Lexicon Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Investments & Acquisitions (3)

To view Lexicon Pharmaceuticals‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 02-Aug-2010 000000000000000000 0000 Pharmaceuticals 000000 00000 00.0
00000000 0000 01-Jun-2007 00000 0000000 Pharmaceuticals 000000 00000 00.0
Coelacanth Chemical 12-Jul-2001 Merger/Acquisition 0000 Pharmaceuticals 000000 00000 00.0

Ready to get started?

Request a free trial